🇺🇸 FDA
Pipeline program

Nivolumab

15-126

Phase 2 small_molecule completed

Quick answer

Nivolumab for Bladder Cancer is a Phase 2 program (small_molecule) at Adaptive Biotechnologies Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
Adaptive Biotechnologies Corp
Indication
Bladder Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials